1. Has the clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban changed in the last 5 years of use?
- Author
-
Moreno Conde M, Pimentel Quezada Y, Bonilla Palomas Jl, Gámez López Al, Gallego de la Sacristana López-Serrano Á, and López Ibáñez Mc
- Subjects
Male ,medicine.medical_specialty ,Population ,Hemorrhage ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Rivaroxaban ,Internal medicine ,Atrial Fibrillation ,medicine ,Humans ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Medical prescription ,education ,Stroke ,Aged ,Retrospective Studies ,Aged, 80 and over ,education.field_of_study ,business.industry ,Patient Selection ,Age Factors ,Retrospective cohort study ,Atrial fibrillation ,Mean age ,medicine.disease ,Treatment Outcome ,Molecular Medicine ,Female ,Cardiology and Cardiovascular Medicine ,business ,Major bleeding ,Factor Xa Inhibitors ,medicine.drug - Abstract
Aim: To analyze the evolution of clinical profile of patients with nonvalvular atrial fibrillation treated with rivaroxaban. Methods: Retrospective study in which patients treated with rivaroxaban were divided into two groups according to the data in which the initial prescription was performed (November 2012–December 2013 and January 2014–January 2017). Results: 211 patients (mean age 76.7 ± 9.2 years; CHA2DS2-VASc 3.8 ± 1.5; HAS-BLED 2.0 ± 0.8.) were included. Age and bleeding risk were higher in those subjects in which the prescription started earlier. Rates of stroke/TIA, major bleeding and intracranial hemorrhage were 2.3/4.2/0.6 events/100 patient-years, respectively. Conclusion: Although, the initial prescription of rivaroxaban was mainly performed in very elderly patients and/or with a higher bleeding risk, this has been extended to the overall nonvalvular atrial fibrillation population.
- Published
- 2018
- Full Text
- View/download PDF